Back to Top
Anti-PD-1 (RMP1-14)
ichorbio's anti-PD-1 (RMP1-14) antibody is cheaper for academia & non-profits and for industry than the equivalent low endotoxin version from Bio X Cell (BE0146).
"In repeated studies we have found ichorbio's RMP1-14 to be more efficacious than the same clone from Bio X Cell"
Leading Immuno-Oncology CRO
35%
cheaper for
academia
58%
cheaper for
industry
RMP1-14
-
-
-
-
Mouse Anti-Mouse PD-1 (RMP1-14) Recombinant Antibody D265A$300.00 - $5,000.00
Citations
A total of 470 articles have been published over the last three years citing RMP1-14, with scientists from 300 organisations in 32 countries contributing to the research. The top authors publishing articles using RMP1-14 in the last three years are show in Table 1 below.
Image 1: The top 10 most prolific authors citing RMP1-14
A breakdown of the main locations of the authors are shown in Image 2 below. In Image 3 we show the main institutes that cite work using RMP1-14.
Top institutions citing RMP1-14
Images kindly provided by OE1.8
Latest Research Articles Using RMP1-14
- Tristan Rupp, Porsolt SAS. Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.
- Jianxin Wang, John Hopkins University School of Medicine. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.
- Atsushi Enomoto, Nagoya University. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.
- Robert Sobol, Multivir. Tumor suppressor immune gene therapy to reverse immunotherapy resistance.
Who Bought This Also Bought
